

## JAAP VERWEIJ



Jaap Verweij, M.D., Ph.D is an Emeritus Professor of Medical Oncology, and former Dean of the Faculty of Medicine at Erasmus University Medical Centre. He served as chair of the Department of Medical Oncology, and chair of the Daniel den Hoed Cancer Center at the Erasmus University Medical Centre from 2008-2013, and as Dean of the Faculty of Medicine and Vice-Chairman of the Board of directors of Erasmus University Medical Center from April 2013 – September 2017. He also served as Founding Dean of the Faculty of Life Sciences at the University of Siegen, Germany, from October 2017 – November 2019.

His main scientific interests are new drug development, including the performance of clinical phase I and early phase II trials, and the inclusion of pharmacokinetics and pharmacodynamics in these studies. He also has a major interest in the design aspects of early clinical studies. Besides his clinical activities, he has been the chairman of the Early Clinical Studies Group of the European Organisation for Research and Treatment of Cancer (EORTC) from 1993-1996, chairman of the EORTC Soft Tissue and Bone Sarcoma Group from 1996-1999, chairman of the EORTC New Treatment Committee, the EORTC New Drug Advisory Committee, and Vice-President of EORTC. He has also been president of the Connective Tissue Oncology Society (CTOS), chairman of the RECIST working group, and chairman of the Scientific Council of the Dutch Cancer Foundation. He has been editor of the European Journal of Cancer and associate editor of the Journal of Clinical Oncology. He served as vice-chairman in the Board of Governors of the Dutch Cancer Foundation from 2011-2019.

He currently serves as member of the Board of the American Society of Clinical Oncology (ASCO), as non-executive Medical Director of Octimet, as senior advisor to the University of Siegen, Germany, and as Managing Director of the Cancer Drug Development Forum (CDDF) in Brussels, Belgium, and as advisor for pharmaceutical companies.

In 2011 Jaap Verweij was appointed as fellow of the Royal Netherlands Academy of Arts and Sciences, and in 2017 as Fellow of the American Society of Clinical Oncology (ASCO).

He has authored or co-authored over 700 scientific papers, and has given numerous lectures on a variety of topics at international meetings.

---